Kastrukoff L F, Oger J J, Hashimoto S A, Sacks S L, Li D K, Palmer M R, Koopmans R A, Petkau A J, Berkowitz J, Paty D W
Division of Neurology, University of British Columbia, Vancouver, Canada.
Neurology. 1990 Mar;40(3 Pt 1):479-86. doi: 10.1212/wnl.40.3_part_1.479.
A randomized, double-blind, placebo-controlled, noncrossover trial determined the efficacy of lymphoblastoid interferon (IFN) in chronic progressive multiple sclerosis (CP MS). Fifty patients received 5 X 10(6) IU IFN subcutaneously daily for 6 months while 50 received placebo. After 2 years, there were no significant differences between the 2 groups based on clinical evaluations and quantitative MRI analysis of the brain, although a trend was observed in the IFN group. Clinically, the IFN group was worse at 1 and 3 months and improved at 6 to 18 months, when compared with the placebo group. Results of MRI evaluations of the brain at 6 months support this trend. This trend likely resulted from a subpopulation of 10 IFN-treated patients, characterized by a higher women:men ratio and a lower EDSS score at entry into the trial. We cannot recommend lymphoblastoid IFN as treatment for CP MS at this time.
一项随机、双盲、安慰剂对照、非交叉试验确定了淋巴母细胞干扰素（IFN）在慢性进展性多发性硬化症（CP MS）中的疗效。50名患者每天皮下注射5×10⁶国际单位IFN，持续6个月，而另外50名患者接受安慰剂治疗。2年后，根据临床评估和脑部定量MRI分析，两组之间没有显著差异，尽管在IFN组中观察到一种趋势。临床上，与安慰剂组相比，IFN组在1个月和3个月时情况较差，在6至18个月时有所改善。6个月时脑部MRI评估结果支持这一趋势。这种趋势可能是由10名接受IFN治疗的患者亚组导致的，其特点是女性与男性比例较高，且进入试验时的扩展残疾状态量表（EDSS）评分较低。目前我们不推荐将淋巴母细胞干扰素作为CP MS的治疗方法。
